The surgical management of breast cancer

Key points
- The surgical management of breast cancer has undergone radical change in the last 40 years.
- The management of the axilla remains controversial.
- The surgical management of breast cancer has undergone considerable change over the last 40 years.
- Does this mean that there is no place for mastectomy in the treatment of breast cancer?
The surgical management of breast cancer has undergone radical change in the last 40 years. While it used to be standard practice to perform mastectomies, new breast-conserving procedures have been developed which have been shown to be as effective as mastectomy in some cases. Mr Udi Chetty reviews the evidence and the criteria for breast-conserving surgery and mastectomy.
The surgical management of breast cancer has undergone considerable change over the last 40 years. The gold standard was formerly the Halsted radical mastectomy, in which the whole of the breast was removed with the pectoralis muscles and axillary contents. The need for this mutilating surgery has been challenged. McWhirter, in Edinburgh, showed that a simple mastectomy plus radiotherapy was as effective as a radical mastectomy. In the 1970s, three groups in Europe and the US set up randomised clinical trials to test the efficacy of breast-conserving surgery (removing the tumour combined with radiotherapy) compared with a radical mastectomy. The long-term results from two of these studies have been published recently in the New England Journal of Medicine (NEJM). Both of these studies show that, after 20 years of follow-up, breast-conserving procedures gave results equivalent to radical mastectomy in terms of death from breast cancer and overall survival.
Does this mean that there is no place for mastectomy in the treatment of breast cancer? Unfortunately not. In both trials patients were selected for entry by the size of the tumour, clinical node status and site of the tumour.
In addition, patients who were initially treated by breast conservation and on histological examination were shown to have a tumour that went to the margin of excision were subsequently treated by mastectomy. Thus, breast-conserving surgery is appropriate for single tumours that are small enough in relation to the size of the breast so as to enable removal with an adequate margin and without causing marked distortion. Confirmation that the margins of excision are clear of tumour is important. However, patients with larger tumours, multifocal tumours or a single invasive tumour with extensive ductal carcinoma in situ are still best treated by a mastectomy.
Key Points
- Radical mastectomy, previously the standard treatment for breast cancer, involves removal of the whole breast, the underlying chest muscles and the contents of the axilla.
- Recent long-term trials have shown that less extensive ‘breast conserving’ surgery gives eqiuvalent survival in selected patients.
- Breast-conserving surgery is now appropriate for patients with breast cancers small enough to allow removal with an adequate margin of disease-free tissue.
- Mastectomy still required for larger and multifocal tumours.
- The best treatment for the contents of the axilla remains to be determined, but recent studies indicate this could be managed by selective rather than radical surgery.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsNYU nursing study examines obesity in relation to breast cancer related lymphedema
Each year, about 1.38 million women worldwide are diagnosed with breast cancer. Advances in treatment have facilitated a 90% five-year survival rate among those treated. Given the increased rate and length of survival…
18 December 2015
NewsNeoadjuvant use of pertuzumab in HER2-positive breast cancer
Pertuzumab (trade name: Perjeta) is approved for two therapeutic indications. Its use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable…
4 December 2015
NewsPotential new therapy for triple-negative breast cancer shows promise in lab studies
Recent laboratory findings provide novel insight into potential new therapeutic approaches for triple-negative breast cancer, a particularly difficult to treat and aggressive form of the disease. In a recent study…
28 October 2015



